Company Overview and News

 
DoubleDragon partners with Equicom for clinics at CityMalls

2018-10-16 bworldonline
DOUBLEDRAGON Properties Corp. said it has partnered with the operator of MyHealth Clinics to open medical clinics in its community malls.
SMIVY SVTMF SM DD

 
DoubleDragon ‘unaffected’ by rising interest rates

2018-10-03 bworldonline
DOUBLEDRAGON Properties Corp. on Wednesday said it is “generally unaffected” by rising interest rates and weakening peso, as the company’s borrowings are all peso-denominated and have fixed rates.
DD

 
Bourse surprises with ‘dizzying rally’

2018-09-21 bworldonline
THE PHILIPPINE STOCK EXCHANGE index (PSEi) exited bear territory on Friday amid what one analyst described as “a dizzying rally”, but its strong recovery was not enough to prevent its third straight week-on-week drop.
FPHPC MPCIY BDOUY AYAAY UVRBY AEV FPHP DD SECB MRAIF BDOUF BDO ABTZY MPI MPCFF SYBJF URC MRC ALI FPH UVRBF AYAAF

 
DoubleDragon profit surges in 2nd quarter

2018-08-14 bworldonline
DOUBLEDRAGON Properties Corp. on Tuesday said its second quarter consolidated net income more than doubled to P513.5 million, boosted by rental revenues from its community malls and offices.
DD

 
Colliers sees more office spaces in Bay Area by 2021

2018-07-23 bworldonline
THE MANILA BAY Area is expected to grow its total office stock by 130% by 2021, as tenants look for alternative locations given the lack of office spaces in Metro Manila’s two leading business districts.
DD

 
DoubleDragon eyes tag as dividend machine

2018-07-13 business.inquirer.net
Property developer DoubleDragon Properties has completed a P4.3-billion re-initial public offering (IPO), a key component of its goal to transform itself into a “recurring dividend machine” in two years.
PSKXF PHSXY PSE DD

8
Capital raised via stock market hits P150 billion in first half

2018-07-01 bworldonline
CAPITAL raised at the stock market reached a record P150 billion in the first half, as companies braved the local market amid prevailing volatility.
IRC PSKXF CHIB SUAFF RBLAY BSC DD CKGOY RLC PHSXY PSE FNI BCDTY

7
DoubleDragon aims for P4.5B in strong re-IPO

2018-06-29 business.inquirer.net
Property developer DoubleDragon Properties has firmed up its reinitial public offering (re-IPO) size at P4.5 billion in an equity deal that has lured foreign investors.
PSKXF PHSXY PSE DD

7
DoubleDragon’s re-IPO priced at P30 per share

2018-06-28 business.inquirer.net
Property developer DoubleDragon Properties has priced its re-initial public offering (re-IPO) at P30 per share, firming up the size of its capital-building program at P4.5 billion.
PSKXF PHSXY PSE DD

2
DoubleDragon starts building 2nd CentralHub

2018-06-19 bworldonline
DOUBLEDRAGON Properties Corp. on Tuesday said it has started construction for its second industrial leasing hub in Iloilo City.
DD

2
DoubleDragon breaks ground on second Iloilo industrial hub

2018-06-19 bworldonline
DoubleDragon Properties Corp. on Tuesday said it has started construction for its second industrial leasing hub in Iloilo.
DD

8
DoubleDragon unveils culinary, heritage ‘village’

2018-06-07 business.inquirer.net - 1
Property developer DoubleDragon Properties Corp. is set to unveil today Islas Pinas, a new Filipino culinary and heritage village developed in collaboration with celebrity chef Margarita Fores, as the centerpiece of its maiden office development DoubleDragon Plaza.
PSKXF PHSXY PSE DD

7
DoubleDragon gets PSE nod for follow-on offering schedule

2018-06-01 bworldonline
DOUBLEDRAGON PROPERTIES Corp. announced on Friday that the stock exchange has approved the updated timetable for its follow-on offering, which could raise up to P6 billion to fund the company’s projects.
PSKXF PHSXY PSE DD

11
Firms brave turbulent market to raise funds

2018-05-31 bworldonline
A FLURRY of fund raising lies ahead this month, even as jarring volatility presents a challenging environment for companies seeking to raise funds on the stock market.
PSKXF RZLLY PHSXY PSE SUAFF DD FNI RCB

7
DoubleDragon secures PSE approval for P6-billion follow-on offering

2018-05-30 bworldonline
DOUBLEDRAGON PROPERTIES Corp. has secured approval from the Philippine Stock Exchange (PSE) to proceed with its follow-on offering worth up to P6 billion.
PSKXF PHSXY PSE DD

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...